Postdischarge thromboprophylaxis and mortality risk after hip- or knee-replacement surgery

CMAJ. Canadian Medical Association Journal

Volumn 178, Issue 12, 2008, Pages 1545-1554

  Rahme, Elham ^a,c   Dasgupta, Kaberi ^a,b   Burman, Mark ^c   Yin, Hongjun ^e   Bernatsky, Sasha ^a,b   Berry, Greg ^c   Nedjar, Hacene ^b   Kahn, Susan R ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; FIBRINOLYTIC AGENT;

AGED; ARTICLE; EMBOLISM PREVENTION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OSTEOARTHRITIS; PROPHYLAXIS; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; HIP ARTHROPLASTY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 45549095821     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071388     Document Type: Article

References (31)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-75S.
2. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
3. Prevention of venous thromboembolism. International consensus statement (guidelines according to scientific evidence). Int Angiol 1997;16:3-38.
4. Pini M, Spyropoulos AC. Prevention of venous thromboembolism. Semin Thromb Hemost 2006;32:755-66.
5. Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994;331:1630-41.
6. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(Suppl 3):338S-400S.
7. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9-15.
8. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002;162:1966-71.
9. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 2003;124:386S-92S.
10. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:287S-310S.
11. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
12. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995;142:428-36.
13. Mayo NE, Danys I, Carlton J, et al. Accuracy of hospital discharge coding for stroke. Can J Cardiol 1993;9(Suppl):121D-4D.
14. Jollis JG, Ancukiewicz M, Delong ER, et al. Discordance of databases designed for claims payment versus clinical in formation-systems - implications for outcomes research. Ann Intern Med 1993;119:844-50.
15. Tamblyn R, Reid T, Mayo N, et al. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000;53:183-94.
16. Roos LL, Sharp SM, Wajda A. Assessing data quality - a computerized approach. Soc Sci Med 1989;28:175-82.
17. Weisberg S. Applied linear regression. 3rd ed. Hoboken (NJ): Wiley-Interscience; 2005.
18. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
19. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001;135:858-69.
20. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-8.
21. Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J Thromb Haemost 2003;1:896-906.
22. Abad JI. Prophylaxis of venous thromboembolism in orthopaedic surgery. Pathophysiol Haemost Thromb 2002;32:403-5.
23. Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 2001;16:679-88.
24. Anderson FA Jr, Hirsh J, White K, et al. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 2003;124:349S-56S.
25. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007;89:799-807.
26. Chia LR, Schlenk EA, Dunbar-Jacob J. Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging 2006;23:191-202.
27. Murray MD, Morrow DG, Weiner M, et al. A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother 2004;2:36-43.
28. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31.
29. Nunley RM, Lachiewicz PF. Mortality after total hip and knee arthroplasty in a medium-volume university practice. J Arthroplasty 2003;18:278-85.
30. Lie SA, Engesaeter LB, Havelin LI, et al. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand 2002;73:392-9.
31. MacDonald TM, Pettitt D, Lee FH, et al. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology (Oxford) 2003;42(Suppl3):iii3-10.